GLP1R and chronic kidney disease: This review aims to synthesize the available clinical evidence on the efficacyand safety of dual Gcg and GLP-1 RAs across the cardiometabolic continuum.Specifically, this review explores the impact of dual Gcg and GLP-1 RAs onglycemic control, weight reduction, surrogate cardiovascular outcomes, andcomorbid conditions, including MASLD and chronic kidney disease (CKD).Additionally, this review highlights the mechanisms of action, safety profiles,and potential advantages of dual agonists compared to existing therapeuticoptions.